News

An open-label extension of the PIONEER trial supports the use of avapritinib as a safe and effective treatment for patients with ISM.

A recent series of case reports shows that unexplained or hard-to-treat osteoporosis can be an early warning sign of SM.

A case report describes a patient with SM-AHN whose diagnostic journey was complicated by an absence of skin involvement.

Researchers developed a targeted nanotherapy that eliminated mast cells with fewer off-target effects than standard treatment.

In a registry study, patients with myeloid SM-AHN had shorter survival, especially when the SM component was advanced.

Cogent submitted an FDA application for bezuclastinib in advanced SM after the APEX trial showed responses and disease marker reductions.

A daily symptom diary works well for tracking symptom severity and changes in adult patients with nonadvanced SM.

A 2026 medical review outlines how doctors diagnose, classify and treat SM in adults, including advances in targeted therapies.

Patients with SM-AHN whose mast cells and blood cancer cells carried different mutations tended to have slower disease and longer survival.

A machine learning model correctly identified up to 97.7% of AHN cases in advanced systemic mastocytosis, EHA2026 data showed.